These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32037130)

  • 41. Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery.
    Bangalore S; Guo Y; Samadashvili Z; Blecker S; Hannan EL
    Circulation; 2016 May; 133(22):2132-40. PubMed ID: 27151532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    von Birgelen C; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man FHAF; Louwerenburg JHW; Hartmann M; Zocca P; Linssen GCM; van der Palen J; Doggen CJM; Löwik MM
    Lancet; 2016 Nov; 388(10060):2607-2617. PubMed ID: 27806902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era.
    Sipahi I; Akay MH; Dagdelen S; Blitz A; Alhan C
    JAMA Intern Med; 2014 Feb; 174(2):223-30. PubMed ID: 24296767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Outcome of Coronary Artery Bypass Grafting Versus Drug-Eluting Stent Implantation for Non-ST-Elevation Acute Coronary Syndrome.
    Chang M; Lee CW; Ahn JM; Cavalcante R; Sotomi Y; Onuma Y; Han M; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Serruys PW; Park SJ
    Am J Cardiol; 2017 Aug; 120(3):380-386. PubMed ID: 28595861
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug-eluting stents versus coronary artery bypass grafting for left-main coronary artery disease.
    Takagi H; Ando T; Umemoto T;
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):697-709. PubMed ID: 28799701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Death and Myocardial Infarction Following Initial Revascularization Versus Optimal Medical Therapy in Chronic Coronary Syndromes With Myocardial Ischemia: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials.
    Soares A; Boden WE; Hueb W; Brooks MM; Vlachos HEA; O'Fee K; Hardi A; Brown DL
    J Am Heart Assoc; 2021 Jan; 10(2):e019114. PubMed ID: 33442990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Percutaneous coronary intervention with drug-eluting stent implantation vs. coronary artery bypass grafting for multivessel coronary artery disease in metabolic syndrome patients with acute myocardial infarction.
    Ahmed K; Jeong MH; Chakraborty R; Hong YJ; Sim DS; Hwang SH; Lee MG; Park KH; Kim JH; Ahn Y; Cho MC; Kim CJ; Kim YJ; Park JC; Kang JC;
    Circ J; 2012; 76(3):721-8. PubMed ID: 22240598
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
    Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Intervention.
    Nagarajarao HS; Ojha CP; Mulukutla V; Ibrahim A; Mares AC; Paul TK
    Curr Cardiol Rep; 2020 Feb; 22(4):16. PubMed ID: 32036460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meta-Analysis of Randomized Controlled Trials of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Left Main Coronary Artery Disease.
    Garg A; Rao SV; Agrawal S; Theodoropoulos K; Mennuni M; Sharma A; Garg L; Ferrante G; Meelu OA; Sargsyan D; Reimers B; Cohen M; Kostis JB; Stefanini GG
    Am J Cardiol; 2017 Jun; 119(12):1942-1948. PubMed ID: 28433215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration.
    Giustino G; Harari R; Baber U; Sartori S; Stone GW; Leon MB; Windecker S; Serruys PW; Kastrati A; Von Birgelen C; Kimura T; Stefanini GG; Dangas GD; Wijns W; Steg PG; Morice MC; Camenzind E; Weisz G; Smits PC; Sorrentino S; Sharma M; Farhan S; Faggioni M; Kandzari D; Galatius S; Jeger RV; Valgimigli M; Itchhaporia D; Mehta L; Kim HS; Chieffo A; Mehran R
    JAMA Cardiol; 2017 Aug; 2(8):855-862. PubMed ID: 28658478
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coronary surgery is superior to drug eluting stents in multivessel disease. Systematic review and meta-analysis of contemporary randomized controlled trials.
    Benedetto U; Gaudino M; Ng C; Biondi-Zoccai G; D'Ascenzo F; Frati G; Girardi LN; Angelini GD; Taggart DP
    Int J Cardiol; 2016 May; 210():19-24. PubMed ID: 26922707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
    Head SJ; Milojevic M; Daemen J; Ahn JM; Boersma E; Christiansen EH; Domanski MJ; Farkouh ME; Flather M; Fuster V; Hlatky MA; Holm NR; Hueb WA; Kamalesh M; Kim YH; Mäkikallio T; Mohr FW; Papageorgiou G; Park SJ; Rodriguez AE; Sabik JF; Stables RH; Stone GW; Serruys PW; Kappetein AP
    Lancet; 2018 Mar; 391(10124):939-948. PubMed ID: 29478841
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biodegradable-Polymer Versus Polymer-Free Drug-Eluting Stents for the Treatment of Coronary Artery Disease.
    Nogic J; Thein P; Mirzaee S; Comella A; Soon K; Cameron JD; West NEJ; Brown AJ
    Cardiovasc Revasc Med; 2019 Oct; 20(10):865-870. PubMed ID: 30578169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials.
    Mancini GBJ; Boden WE; Brooks MM; Vlachos H; Chaitman BR; Frye R; Bittner V; Hartigan PM; Dagenais GR
    Atherosclerosis; 2018 Oct; 277():186-194. PubMed ID: 29861270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.